Literature DB >> 12878361

MHC class I chain-related gene A transmembrane polymorphism modulates the extension of ulcerative colitis.

Juan Luis Fdez-Morera1, Luis Rodrigo, Antonio López-Vázquez, Sandra R Rodero, Jesús Martínez-Borra, Pilar Niño, Segundo González, Carlos López-Larrea.   

Abstract

Recent evidence from several studies has suggested a genetic predisposition in the pathogenesis of ulcerative colitis (UC), which is especially related with major histocompatibility complex (MHC) genes. The aim of this study was to investigate the possible association of human leukocyte antigen (HLA-B, HLA-DR) and MHC class I chain-related-transmembrane (MICA-TM) polymorphism with the behavior and extension of UC. We selected 121 unrelated patients with UC. These were divided into two groups according to the extension of the disease: 31 patients with distal UC and 90 with wide extension UC; 116 blood donors were also selected as healthy controls, all of whom were typed for HLA-B, HLA-DR, and MICA-TM alleles. HLA-B7 was found to be overrepresented in distal UC patients compared with those with extensive UC (p(c) = 0.007, OR = 5.33) and healthy controls (p(c) = 0.03, OR = 4.09). The MICA-A5.1 allele was also increased in distal UC (p(c) = 0.015, OR = 3.82) when compared with extensive forms. These alleles are in strong linkage disequilibrium in our population. The MICA-A5 allele was significantly increased in extensive forms when compared with healthy controls(p(c) = 0.02, OR = 2.4). According to our results, MICA-A5.1 allele seems to be protective against extensive forms of UC, and MICA-A5 may condition a worse progression of the disease. These results are in agreement with other studies that suggest a similar role of such alleles in other diseases, such as insulin-dependent diabetes mellitus and celiac disease.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12878361     DOI: 10.1016/s0198-8859(03)00121-6

Source DB:  PubMed          Journal:  Hum Immunol        ISSN: 0198-8859            Impact factor:   2.850


  8 in total

1.  Role of major histocompatibility complex class I-related molecules A*A5.1 allele in ulcerative colitis in Chinese patients.

Authors:  Min Lü; Bing Xia; Liuqing Ge; Yi Li; Jie Zhao; Fan Chen; Feng Zhou; Xiaolian Zhang; Jinquan Tan
Journal:  Immunology       Date:  2008-11-07       Impact factor: 7.397

2.  MICB0106 gene polymorphism is associated with ulcerative colitis in central China.

Authors:  Yi Li; Bing Xia; Min Lü; Liuqing Ge; Xiaolian Zhang
Journal:  Int J Colorectal Dis       Date:  2009-08-07       Impact factor: 2.571

3.  MICA polymorphisms and cancer risk: a meta-analysis.

Authors:  Mengyao Ji; Jun Wang; Lei Yuan; Yunting Zhang; Jixiang Zhang; Weiguo Dong; Xiulan Peng
Journal:  Int J Clin Exp Med       Date:  2015-01-15

Review 4.  Genetics of inflammatory bowel disease: the role of the HLA complex.

Authors:  Tariq Ahmad; Sara-E Marshall; Derek Jewell
Journal:  World J Gastroenterol       Date:  2006-06-21       Impact factor: 5.742

5.  MHC class I chain-related gene A-A5.1 allele is associated with ulcerative colitis in Chinese population.

Authors:  Yijuan Ding; Bing Xia; Min Lü; Yan Zhang; Jin Li; Mei Ye; Hesheng Luo; Jieping Yu; Xiaolian Zhang; Jingquan Tan
Journal:  Clin Exp Immunol       Date:  2005-10       Impact factor: 4.330

6.  MICA*A4 protects against ulcerative colitis, whereas MICA*A5.1 is associated with abscess formation and age of onset.

Authors:  A Martinez-Chamorro; A Moreno; M Gómez-García; M J Cabello; J Martin; M Á Lopez-Nevot
Journal:  Clin Exp Immunol       Date:  2016-04-05       Impact factor: 4.330

7.  Associations of MICA Polymorphisms with Inflammatory Rheumatic Diseases.

Authors:  Qingwen Wang; Xiaodong Zhou
Journal:  Open Rheumatol J       Date:  2015-11-24

Review 8.  Gut Mesenchymal Stromal Cells in Immunity.

Authors:  Valeria Messina; Carla Buccione; Giulia Marotta; Giovanna Ziccheddu; Michele Signore; Gianfranco Mattia; Rossella Puglisi; Benedetto Sacchetti; Livia Biancone; Mauro Valtieri
Journal:  Stem Cells Int       Date:  2017-02-28       Impact factor: 5.443

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.